2025-08-29 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc (TMDX) based on the provided data.

**Report on Transmedics Group Inc (TMDX)**

**1. Performance Overview & Comparative Analysis**

*   **Ticker:** TMDX
*   **Company Description:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care systems for transplantation therapy.

**Key Performance Metrics:**

*   **TMDX Total Return:** 219.24%
*   **S&P 500 (VOO) Total Return:** 74.16%
*   **Absolute Deviation (TMDX - VOO):** 293.4
*   **Deviation Range (Min: -88.7, Max: 594.7)**
*   **Relative Deviation:** 55.9

**Analysis:** TMDX has significantly outperformed the S&P 500 over the observed period. The relative deviation suggests that while the stock has shown strong upside, it is currently in the upper half of its historical performance range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|-------|-------|------|--------|
| 2019-2021  | -4.0%  | 63.4% | -52.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0% | 68.3% | 138.0% | 0.1  | 2.1    |
| 2021-2023  | 95.0%  | 69.4% | 77.0%  | 0.2  | 2.7    |
| 2022-2024  | 147.0% | 82.8% | 121.0% | 0.2  | 2.1    |
| 2023-2025  | 100.0% | 82.8% | 46.0%  | 0.5  | 4.0    |

**Analysis:**

*   **CAGR:** Transmedics Group Inc. has demonstrated substantial Compound Annual Growth Rate (CAGR) over multiple periods, indicating strong growth momentum. However, the period from 2019 to 2021 shows a negative CAGR of -4.0%, which may be due to initial challenges or market conditions.
*   **MDD (Maximum Drawdown):** The MDD values are consistently high across all periods, ranging from 63.4% to 82.8%. This suggests the stock experiences significant price volatility and potential for large declines from peak to trough, indicating higher risk.
*   **Alpha:** Alpha is notably positive in most periods, indicating that Transmedics Group Inc. has outperformed its benchmark (typically the S&P 500) after adjusting for risk. However, the 2019-2021 period shows a negative Alpha of -52.0%, which suggests underperformance relative to the benchmark.
*   **Beta:** Beta values range from 0.0 to 0.5, indicating that the stock's volatility is generally lower than the market average (Beta = 1). However, the Beta increases in later periods, suggesting that the stock's correlation with the market is strengthening over time.
*   **Cap(B):** Market capitalization has generally increased over time, indicating that the company has grown in size.

**2. Recent Stock Performance**

*   **Current Price:** $116.725
*   **Previous Close:** $117.38
*   **Price Change:** -$0.56 (Slight decrease)
*   **5-Day Moving Average:** 116.821
*   **20-Day Moving Average:** 122.2493
*   **60-Day Moving Average:** 123.4688

**Analysis:** The stock price has experienced a slight decrease in the most recent trading session. The current price is below the 20-day and 60-day moving averages, suggesting a potential short-term downward trend.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.3266 (Low Risk)
*   **RSI:** 52.79
*   **PPO:** -0.8186
*   **Hybrid Signal:** cash_60%_Sell 0.1% of holdings (1 shares - Caution - MRI:0.33) (Cash Ratio: 60% on 2025-08-28)
*   **Recent Relative Deviation Change (20-day):** -7.0 (Short-term decline)
*   **Expected Return:** 145.3% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates low market risk, which is a positive sign.
*   The RSI is near neutral, suggesting neither overbought nor oversold conditions.
*   The PPO is slightly negative, reinforcing the potential for a short-term downward trend.
*   The hybrid signal suggests a cautious approach, advising a slight reduction in holdings.
*   The recent negative change in relative deviation and the small negative change in price confirms a very recent downward trend.
*   The high expected return indicates strong potential for outperformance in the long term (2+ years) if investing steadily.

**4. Recent News & Events**

*   **Volatility:** Recent news indicates that the stock has experienced notable volatility.
*   **Analyst Discussions:** Analysts are actively discussing the company's recent performance and outlook.
*   **Major Business Developments/Regulatory Changes/Market Events:** The company has been in the news due to significant developments.

**Analysis:** These news items suggest that the company is undergoing changes and is subject to market attention. Investors should monitor these developments.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** Transmedics has consistently exceeded EPS expectations in recent quarters, particularly in the last two reported quarters. This indicates strong earnings performance. However, in 2024-10-28 the EPS was lower than expected.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.16B  | 61.38%        |
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.32B  | 10.97%  |
| 2025-03-31 | $0.27B  | 9.64%   |
| 2024-12-31 | $0.23B  | 3.00%   |
| 2024-09-30 | $0.21B  | 2.01%   |
| 2024-06-30 | $0.19B  | 6.42%   |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing over the past five quarters, indicating strong sales growth.
*   **Profit Margin:** The profit margin is very high and relatively stable, suggesting efficient operations.
*   **Equity:** Equity has also been steadily increasing, showing the company's financial health and growth.
*   **ROE:** Return on Equity (ROE) has improved significantly, indicating better profitability from shareholder equity.

**7. 종합적인 분석 (Overall Analysis)**

Transmedics Group Inc. (TMDX) exhibits strong growth potential and has significantly outperformed the S&P 500. The company shows promising financial health with increasing revenue, high profit margins, and a rising ROE. Recent earnings have consistently exceeded expectations.

However, the stock is volatile and has experienced significant drawdowns in the past. Short-term technical indicators suggest a possible downward trend, and analysts are actively discussing the company due to recent news and market volatility.

**Recommendation:**

Given the strong long-term growth prospects and high expected returns, a long-term accumulative investment strategy (investing consistently over time) in TMDX could be considered. However, investors should be aware of the stock's volatility and carefully monitor recent news and company announcements. The hybrid signal suggests a cautious approach, so gradually building a position might be prudent.
